Flt3L treatment expands a population of ILC type 1 cells differently from NK cells. (A) Representative flow cytometry analysis of TBET and CD127 expression on Lin⁻CD7⁺ cells in liver of a PBS- and a littermate Flt3L-treated BRGSF mouse. (B) Expression of CD117, EOMES, CD161, and CD94 (histograms) on liver TBET⁺CD127⁻ (red), TBET⁺CD127⁺ (blue), and TBET⁻CD127⁺ cells (gray) assessed by flow cytometry. (C) Expression of CD127, CD16, and NKp46 on liver Lin⁻TBET⁺ cells, assessed by flow cytometry. (D) Frequency among hCD45⁺ cells (left) and total number (right) of Lin⁻CD7⁺CD127⁺TBET⁺ liver cells. (E) Representative functional analysis by IFN-γ intracellular flow cytometry after phorbol 12-myristate 13-acetate/ionomycin plus cytokine 4-hour stimulation of TBET⁺CD127⁻ (red) and TBET⁺CD127⁺ (blue) cells. Gated cells were determined using unstimulated controls. (F) Flow cytometry representation of IFN-γ production by Lin⁻CD127⁺TBET⁺CD161⁺ ILC1 cells in response to TLR-mediated in vivo stimulation. Composite data from of 3 to 4 mice per condition are shown at left. Numbers in plots represent frequencies within gates.